Community post

The Cystic Fibrosis Foundation announced they will provide up to $5M to support Armata Pharmaceuticals in conducting a Phase 1b/2 clinical trial to test the safety and tolerability of phage therapy in Pseudomonas aeruginosa infections in people living with cystic fibrosis.